©The Author(s) 2025.
World J Gastroenterol. Nov 7, 2025; 31(41): 110955
Published online Nov 7, 2025. doi: 10.3748/wjg.v31.i41.110955
Published online Nov 7, 2025. doi: 10.3748/wjg.v31.i41.110955
Table 2 Clinical characteristics of patients, n (%)
| Crohn’s disease | Ulcerative colitis | |
| n | 21 | 18 |
| Time of disease (years) | 11.3 ± 9.0 | 13.0 ± 8.5 |
| Treatment | ||
| Corticoids | 6 (28.6) | 2 (11.1) |
| 5-aminosalicylic acid | 3 (14.3) | 14 (77.8) |
| Sulfasalazine | 3 (14.3) | 1 (5.6) |
| Azathioprine | 4 (19.0) | 4 (22.2) |
| anti-TNF | 3 (14.3) | 1 (5.6) |
| Disease phenotype | Inflammatory 8 (38.1) | Left-sided colitis 8 (44.4) |
| Stricturing 4 (19.0) | Extensive colitis 9 (50.0) | |
| Fistulizing 7 (33.3) |
-
Citation: Ruiz-Malagón AJ, Herraiz-Vilela M, Serrano-Pino R, García-Ávila P,
Díaz- Suárez L, Carmona-Segovia AD, Becerra-Munoz VM, Jiménez-Navarro M, Arranz-Salas I, López-Villodres JA, Fernández-Castañer A, Gutiérrez-Martínez F, Rodríguez-González FJ, Camargo-Camero R, Alcaín-Martínez G, Rodríguez-Díaz C, García-Fuentes E, Sánchez-Quintero MJ, López-Gómez C. Growth differentiation factor 15 alters intestinal barrier and increases permeability: A new molecular target in inflammatory bowel disease. World J Gastroenterol 2025; 31(41): 110955 - URL: https://www.wjgnet.com/1007-9327/full/v31/i41/110955.htm
- DOI: https://dx.doi.org/10.3748/wjg.v31.i41.110955